Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 44 of 1,261
  1. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  2. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  3. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  4. US 12290531

    Compositions targeting BCMA and methods of use thereof

    Takeda Pharmaceutical Company Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  5. US 12291548

    Compounds, compositions, and methods for the treatment of disease

    Sperovie Biosciences, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  6. US 12290524

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  7. US 12290505

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  8. US 12290069

    Pest control using natural pest control agent blends

    TYRATECH, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  9. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Indivior UK Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  10. US 12290588

    Peptide having activity of improving skin condition and use thereof

    CAREGEN CO., LTD. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  11. US 12290520

    Methods of use of emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  12. US 12290569

    Methods and compositions using peptides and proteins with c-terminal elements

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted May 6, 2025 · Expires May 1, 2045

    granted
  13. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Granted May 6, 2025 · Expires May 1, 2045

    granted
  14. US 12292445

    Methods of selecting subjects for treatment with metabolomic modulators

    The Regents of the University of California · Granted May 6, 2025 · Expires May 1, 2045

    granted
  15. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  16. US 12291556

    Parathyroid hormone variants

    Takeda Pharmaceutical Company Limited · Granted May 6, 2025 · Expires May 1, 2045

    granted
  17. US 12290567

    Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates

    ARCTURUS THERAPEUTICS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  18. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  19. US 12291560

    Dimerizing agent regulated immunoreceptor complexes

    REGENERON PHARMACEUTICALS, INC. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  20. US 12291557

    Chimeric TIM4 receptors and uses thereof

    Cero Therapeutics Holdings, Inc. · Granted May 6, 2025 · Expires May 1, 2045

    granted
  21. US 12291507

    Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted May 6, 2025 · Expires May 1, 2045

    granted
  22. US 12291502

    Topoisomerase II-alpha inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted May 6, 2025 · Expires May 1, 2045

    granted
  23. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Granted May 6, 2025 · Expires May 1, 2045

    granted
  24. US 12292441

    Recombinant Acinetobacter baumannii strain AB5075

    The Government of the United States, as represented by the Secretary of the Army · Granted May 6, 2025 · Expires May 1, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.